<i id='9E4C2AC16F'><strike id='9E4C2AC16F'><tt id='9E4C2AC16F'><pre id='9E4C2AC16F'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Drug repurposing or repositioning? The language matters 
Making AI in medicine accessible to smaller, and rural hospitals 
Cancer drug shortages should be causing more outrage 
Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more 
Jerome Adams on the need for new antivirals for Covid 
It shouldn't be easy to buy synthetic DNA to recreate a deadly virus 
Hollywood unions extend contract negotiations for actors 
Readout LOUD podcast: What to know about H5N1 bird flu 
Sports medicine is finally prioritizing gender equality 
Shionogi licenses Pompe disease therapy from Maze Therapeutics 
Walensky prepares to leave CDC — and Congress — behind 
Telehealth startups turn to complex chronic diseases
Walensky prepares to leave CDC — and Congress — behind 
Google says AlphaFold 3 can map a vast universe of biomolecules 
Heart attack and stroke risk calculators need revising 
